Abivax (ABVX) Net Income towards Common Stockholders: 2022-2025
Historic Net Income towards Common Stockholders for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$54.8 million.
- Abivax's Net Income towards Common Stockholders fell 31.26% to -$54.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$151.6 million, marking a year-over-year decrease of 71.69%. This contributed to the annual value of -$188.3 million for FY2024, which is 18.48% down from last year.
- As of Q2 2025, Abivax's Net Income towards Common Stockholders stood at -$54.8 million, which was up 0.52% from -$55.1 million recorded in Q1 2025.
- In the past 5 years, Abivax's Net Income towards Common Stockholders ranged from a high of -$66.11 in Q4 2022 and a low of -$55.1 million during Q1 2025.
- Its 3-year average for Net Income towards Common Stockholders is -$33.0 million, with a median of -$44.2 million in 2024.
- Data for Abivax's Net Income towards Common Stockholders shows a maximum YoY slumped of 107.34% (in 2023) over the last 5 years.
- Abivax's Net Income towards Common Stockholders (Quarterly) stood at -$66.11 in 2022, then crashed by 107.34% to -$137.07 in 2023, then crashed by 34.79% to -$184.76 in 2024, then tumbled by 31.26% to -$54.8 million in 2025.
- Its last three reported values are -$54.8 million in Q2 2025, -$55.1 million for Q1 2025, and -$184.76 during Q4 2024.